MX388743B - Conjugados oligonucleótido-péptido. - Google Patents
Conjugados oligonucleótido-péptido.Info
- Publication number
- MX388743B MX388743B MX2017014806A MX2017014806A MX388743B MX 388743 B MX388743 B MX 388743B MX 2017014806 A MX2017014806 A MX 2017014806A MX 2017014806 A MX2017014806 A MX 2017014806A MX 388743 B MX388743 B MX 388743B
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotide
- peptide conjugates
- peptide
- conjugates
- peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a oligonucleótidos, péptidos y conjugados oligonucleótido-péptido; se proporcionan también en la presente métodos para tratar una enfermedad muscular, una infección viral o una infección bacteriana en un sujeto que lo necesita, que comprende administrar al sujeto oligonucleótidos, péptidos y conjugados oligonucleótido-péptido descritos en la presente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163960P | 2015-05-19 | 2015-05-19 | |
| US201662337536P | 2016-05-17 | 2016-05-17 | |
| PCT/US2016/033276 WO2016187425A1 (en) | 2015-05-19 | 2016-05-19 | Peptide oligonucleotide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014806A MX2017014806A (es) | 2018-05-11 |
| MX388743B true MX388743B (es) | 2025-03-20 |
Family
ID=57320822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014806A MX388743B (es) | 2015-05-19 | 2016-05-19 | Conjugados oligonucleótido-péptido. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10675356B2 (es) |
| EP (2) | EP3297649B1 (es) |
| JP (2) | JP6954843B2 (es) |
| KR (2) | KR102644053B1 (es) |
| CN (2) | CN114681621B (es) |
| AU (1) | AU2016264471B2 (es) |
| CA (1) | CA2986228A1 (es) |
| DK (1) | DK3297649T5 (es) |
| ES (1) | ES2964695T3 (es) |
| FI (1) | FI3297649T3 (es) |
| HK (1) | HK1252759A1 (es) |
| HR (1) | HRP20231431T1 (es) |
| IL (1) | IL255655B (es) |
| MA (1) | MA42134A (es) |
| MX (1) | MX388743B (es) |
| NZ (1) | NZ737757A (es) |
| WO (1) | WO2016187425A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675356B2 (en) * | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| CN109757108A (zh) | 2016-07-05 | 2019-05-14 | 比奥马林技术公司 | 具有治疗遗传疾病的改善特征的包含双环支架部分的前体mRNA剪接转换或调节寡核苷酸 |
| SG10202107429WA (en) * | 2017-01-06 | 2021-08-30 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| KR102279333B1 (ko) | 2017-03-07 | 2021-07-20 | 주식회사 만도 | 차량의 디스플레이 시스템 및 이의 구동 방법 |
| GB2580569B (en) * | 2017-06-28 | 2021-08-18 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| JP2020537497A (ja) * | 2017-09-22 | 2020-12-24 | アビディティー バイオサイエンシーズ，インク． | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
| CN111655268B (zh) | 2017-10-04 | 2024-03-26 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
| JP7356416B2 (ja) * | 2017-10-17 | 2023-10-04 | サレプタ セラピューティクス， インコーポレイテッド | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| US12168059B2 (en) * | 2018-07-30 | 2024-12-17 | Sarepta Therapeutics, Inc. | Trimeric peptides for antisense delivery |
| AU2019316103B2 (en) | 2018-08-02 | 2026-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| EP3959319A4 (en) | 2019-04-25 | 2023-06-07 | Avidity Biosciences, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS FOR MULTI-EXON SKIPPING |
| JP7581252B2 (ja) | 2019-06-06 | 2024-11-12 | アビディティー バイオサイエンシーズ，インク． | Ｕｎａアミダイトおよびその使用 |
| US11578090B2 (en) | 2019-06-06 | 2023-02-14 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| AU2020411964A1 (en) | 2019-12-26 | 2022-06-16 | National Center Of Neurology And Psychiatry | Antisense nucleic acid that induces skipping of exon 50 |
| PE20230237A1 (es) | 2020-02-28 | 2023-02-07 | Nippon Shinyaku Co Ltd | Acidos nucleicos antisentido que inducen la omision del exon 51 |
| AU2021237465A1 (en) | 2020-03-19 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| US20250302979A1 (en) * | 2021-04-02 | 2025-10-02 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping |
| AU2022298028A1 (en) | 2021-06-23 | 2023-12-21 | National Center Of Neurology And Psychiatry | Combination of antisense oligomers |
| WO2023282346A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 析出抑制剤 |
| JPWO2023282344A1 (es) | 2021-07-08 | 2023-01-12 | ||
| IL310003A (en) | 2021-07-08 | 2024-03-01 | Nippon Shinyaku Co Ltd | Nephrotoxicity reducing agent |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4370677A1 (en) | 2021-07-16 | 2024-05-22 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Oligonucleotide for inhibiting quaking activity |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| CN120129745A (zh) | 2022-03-10 | 2025-06-10 | 日本新药株式会社 | 抗病毒反义低聚物 |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| JP2025515168A (ja) | 2022-05-06 | 2025-05-13 | アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム | オリゴヌクレオチド |
| EP4594520A2 (en) | 2022-09-30 | 2025-08-06 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
| CN121569035A (zh) * | 2023-07-04 | 2026-02-24 | 大睿生物医药科技(上海)有限公司 | 包含肽的寡核苷酸递送配体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| AU5661386A (en) | 1985-03-15 | 1986-10-13 | Stirchak, E. | Stereoregular polynucleotide-binding polymers |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US6559279B1 (en) * | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| CA2884340C (en) | 2007-11-15 | 2017-07-25 | Sarepta Therapeutics, Inc. | Method of synthesis of morpholino oligomers |
| WO2010048568A1 (en) * | 2008-10-23 | 2010-04-29 | Targeted Growth, Inc. | Modified photosynthetic microorganisms for producing triglycerides |
| EP2762567B1 (en) * | 2008-10-24 | 2016-07-13 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| ES2574625T3 (es) * | 2009-11-25 | 2016-06-21 | Elitechgroup B.V. | Antagonistas de miARN de oligonucleótido conjugado con aglutinante del surco menor (MGB) |
| CN102712927B (zh) * | 2009-12-16 | 2017-12-01 | 库尔纳公司 | 通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病 |
| PL2623507T3 (pl) | 2010-09-30 | 2017-03-31 | Nippon Shinyaku Co., Ltd. | Pochodna kwasu morfolinonukleinowego |
| EP2699269A1 (en) * | 2011-04-22 | 2014-02-26 | Prosensa Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) |
| WO2012150960A1 (en) * | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
| EP2785729B1 (en) | 2011-11-30 | 2020-11-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| PT2788487T (pt) * | 2011-12-08 | 2018-07-03 | Sarepta Therapeutics Inc | Análogos de oligonucleótido visando lmna humano |
| CA2868174A1 (en) * | 2012-03-20 | 2013-09-26 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| AU2013285698A1 (en) * | 2012-07-03 | 2015-02-19 | Biomarin Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| MX369519B (es) * | 2012-09-25 | 2019-11-11 | Genzyme Corp | Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica. |
| NZ732507A (en) | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| US20180216111A1 (en) | 2015-02-27 | 2018-08-02 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| US10675356B2 (en) * | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
-
2016
- 2016-05-19 US US15/574,734 patent/US10675356B2/en active Active
- 2016-05-19 WO PCT/US2016/033276 patent/WO2016187425A1/en not_active Ceased
- 2016-05-19 KR KR1020177035825A patent/KR102644053B1/ko active Active
- 2016-05-19 EP EP16797300.7A patent/EP3297649B1/en active Active
- 2016-05-19 HR HRP20231431TT patent/HRP20231431T1/hr unknown
- 2016-05-19 CN CN202210279461.1A patent/CN114681621B/zh active Active
- 2016-05-19 DK DK16797300.7T patent/DK3297649T5/da active
- 2016-05-19 CN CN201680041867.9A patent/CN107921092B/zh active Active
- 2016-05-19 NZ NZ737757A patent/NZ737757A/en unknown
- 2016-05-19 JP JP2017560238A patent/JP6954843B2/ja active Active
- 2016-05-19 CA CA2986228A patent/CA2986228A1/en active Pending
- 2016-05-19 EP EP23195508.9A patent/EP4306538A3/en active Pending
- 2016-05-19 MX MX2017014806A patent/MX388743B/es unknown
- 2016-05-19 KR KR1020247007058A patent/KR20240035901A/ko active Pending
- 2016-05-19 HK HK18112084.2A patent/HK1252759A1/zh unknown
- 2016-05-19 FI FIEP16797300.7T patent/FI3297649T3/fi active
- 2016-05-19 ES ES16797300T patent/ES2964695T3/es active Active
- 2016-05-19 MA MA042134A patent/MA42134A/fr unknown
- 2016-05-19 AU AU2016264471A patent/AU2016264471B2/en active Active
-
2017
- 2017-11-14 IL IL255655A patent/IL255655B/en unknown
-
2020
- 2020-04-28 US US16/860,292 patent/US11097011B2/en active Active
- 2020-11-05 JP JP2020185083A patent/JP2021011505A/ja active Pending
-
2021
- 2021-08-16 US US17/403,403 patent/US11672871B2/en active Active
-
2023
- 2023-04-06 US US18/296,697 patent/US12239715B2/en active Active
-
2025
- 2025-01-17 US US19/029,784 patent/US20260014263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388743B (es) | Conjugados oligonucleótido-péptido. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| MX2024009339A (es) | Biomarcadores utiles en el diagnostico de infecciones bacterianas y virales. | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| WO2017030823A3 (en) | Anti-tigit antibodies | |
| WO2013130703A3 (en) | Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use | |
| MX2018007307A (es) | Conjugados de peptidos y oligonucleotidos. | |
| MX2014004862A (es) | Formulaciones de polimero acrilico. | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| WO2016011324A3 (en) | 5'-triphosphate oligoribonucleotides | |
| WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| WO2014140166A3 (en) | Vaccine | |
| UA117563C2 (uk) | Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл | |
| EA201791442A1 (ru) | Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров | |
| EA201792539A1 (ru) | Пептид-олигонуклеотидные конъюгаты | |
| EP3382012A4 (en) | LIVING VIRUS WITH A BANK OF ATTENUATED TREES OF DENGUEVIRUS AND DENGUE VACCINE THEREFORE AS ANTIGENE | |
| EA201691835A1 (ru) | Аллостерические модуляторы капсидного белка гепатита в | |
| EA202091619A3 (ru) | Антитела против tigit |